SLC5A2 and kidney failure: Extrapolating data from this analysis highlights the potential benefits of early SGLT2 inhibitor initiation, suggesting that treatment initiation (vs no initiation) when a patient has an eGFR of 60 mL/min/1.73 m2 could potentially delay kidney failure by approximately 11 years, whereas initiation at an eGFR of 30 mL/min/1.73 m2 could delay kidney failure by approximately 6 years (Figure 2).51